Describe the phases of drug development and the design and ethics of clinical trials. Add a note on pharmacogenomics.

Stages of Drug Development

Design of a Randomised Controlled Trial

• Control group — placebo where no effective treatment exists, or the standard treatment where one does; withholding effective treatment to use a placebo is unethical
• Randomisation — allocation by chance, which distributes both known and unknown confounders evenly between the groups. This is what makes the comparison valid and is the single most important design feature
• Allocation concealment — the person enrolling must not know which group the next patient will enter, or selection bias creeps in before randomisation takes effect
• Blinding — single (patient), double (patient and investigator) or triple (adding the analyst). It prevents both the placebo response and biased assessment of outcome
• Intention TO treat analysis — patients are analysed in the group to which they were randomised, whatever happened afterwards. Analysing only those who completed treatment ("per protocol") destroys the benefit of randomisation, because dropping out is not random
• Predefined primary endpoint and sample size, calculated to give adequate power; multiple post-hoc analyses generate false positives
• Crossover design — each patient receives both treatments in random order and acts as their own control; efficient, but only suitable for stable chronic conditions, and requires a washout period

Ethical Requirements

• Declaration OF helsinki and ICH-GCP guidelines, with the ICMR National Ethical Guidelines and the New Drugs and Clinical Trials Rules 2019 in India
• Approval by an institutional ethics committee before any subject is enrolled
• Informed consent — written, in a language the participant understands, covering purpose, procedures, risks, benefits, alternatives, confidentiality, compensation, and the right to withdraw at any time without penalty. Audio-visual recording is required for vulnerable participants in India
• Registration with the Clinical Trials Registry-India (CTRI) before enrolment, and publication of results whatever they show — selective publication of positive trials distorts the entire evidence base
• Compensation for trial-related injury or death is a statutory requirement in India, introduced after serious concerns about the conduct of trials in vulnerable populations
• Data and Safety Monitoring Board — an independent body that may stop a trial early for harm, for overwhelming benefit, or for futility
• Special protection for vulnerable groups — children, pregnant women, prisoners, the mentally ill, and the illiterate or economically disadvantaged

Pharmacogenomics and Personalised Therapy

Drug Regulation and Approval in India

• The central drugs standard control organisation (CDSCO), headed by the Drugs Controller General of India, is the national regulatory authority
• Governed by the Drugs and Cosmetics Act 1940 and Rules 1945, and the New Drugs and Clinical Trials Rules 2019, which set defined timelines for approval, compulsory compensation for trial injury, and requirements for ethics committee registration
• Schedules worth knowing — Schedule H (prescription-only), Schedule H1 (certain antibiotics and antitubercular drugs, requiring a separate register to limit over-the-counter sale), Schedule X (narcotics and psychotropics, requiring a special licence), and Schedule M (good manufacturing practice)
• Narcotic Drugs and Psychotropic Substances Act — amendments have improved access to oral morphine for cancer pain, which had been severely restricted by the original licensing requirements
• The Pharmacovigilance Programme of India feeds post-marketing safety data back to the regulator, and has led to the banning of many irrational fixed-dose combinations
• India is a major global supplier of generic medicines, and its regulatory standards therefore matter well beyond its own borders

Applied Aspects

• Read a trial critically — who was excluded, what the primary endpoint was, whether it was changed, whether the analysis was by intention to treat, and whether a surrogate endpoint was used in place of an outcome that matters
• A surrogate endpoint can mislead completely — the cast trial found that suppressing ventricular ectopics after infarction with flecainide increased mortality, though the surrogate improved
• Relative risk reduction sounds impressive and absolute risk reduction is what matters; the number needed to treat translates a trial result into something usable at the bedside
• India conducts a large and growing share of global clinical trials, and the regulatory framework was substantially tightened after documented failures of consent and compensation; understanding these rules is part of medical training here
• Post-marketing surveillance depends on clinicians reporting, and a doctor who never reports an adverse reaction is a gap in the system rather than a neutral participant
• Pharmacogenomic testing is becoming affordable, and some tests — G6PD, HLA-B*15:02, TPMT — are already justified in Indian practice on cost and benefit alone
• An equivalence or non-inferiority trial answers a different question from a superiority trial, and a non-significant result in the latter does not mean the treatments are equivalent
• Absence of evidence is not evidence of absence — an underpowered trial that fails to show a difference has shown nothing, and this is a frequent misreading
• Check who funded the trial and who analysed the data; industry-funded trials are more likely to report favourable results, which does not make them wrong but does warrant care
• Bioequivalence, not a full trial programme, is what a generic must demonstrate — the same active ingredient at a comparable rate and extent of absorption, which is why generics are cheap and, for most drugs, entirely appropriate
• Narrow-index drugs are the exception — antiepileptics, warfarin, ciclosporin and levothyroxine, where a stable patient is best kept on one preparation and monitored if it changes
• Consent is a process rather than a signature, and in a population with limited literacy and a strong expectation of deference, ensuring it is genuinely informed takes real effort
• Trial participants are not receiving treatment; the distinction between research and care must be explicit, and the therapeutic misconception is common and must be actively corrected
• Publish negative results — selective publication of favourable trials distorts the entire evidence base, and registration before enrolment exists precisely to make suppression visible